Philip Laws
Novartis (Switzerland)(CH)University of Leeds(GB)Bristol-Myers Squibb (Germany)(DE)Eli Lilly (United States)(US)Pfizer (United Kingdom)(GB)Leo Pharma (Australia)(AU)Chapel Allerton Hospital(GB)Leeds Teaching Hospitals NHS Trust(GB)Janssen (France)(FR)Samsung (United States)(US)NIHR Leeds Musculoskeletal Biomedical Research Unit(GB)Galderma (France)(FR)Boehringer Ingelheim (India)(IN)Almirall (Spain)(ES)NIHR Manchester Biomedical Research Centre(GB)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Spondyloarthritis Studies and Treatments, Autoimmune Bullous Skin Diseases
Most-Cited Works
- → Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis(2022)140 cited
- → No Deaths Associated with Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose(2011)105 cited
- → IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis(2018)82 cited
- → Topical treatment of psoriasis(2010)75 cited
- → Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers(2023)70 cited
- → Childhood Mycosis Fungoides: Experience of 28 Patients and Response to Phototherapy(2014)67 cited